预约演示
更新于：2025-01-10
Avenciguat
更新于：2025-01-10
概要
基本信息
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C34H38N4O5 |
InChIKeyKWNFFNFBUMFTHK-UHFFFAOYSA-N |
CAS号1579514-06-9 |
关联
22
项与 Avenciguat 相关的临床试验NCT06272058
Pharmacokinetics, Safety, and Tolerability of BI 685509 in Subjects With Severe Liver Impairment (Child-Pugh Classification C) as Compared to Healthy Subjects
CTR20234147
在发生首次失代偿事件后病情稳定（CTP5-7）的失代偿期肝硬化伴临床显著性门静脉高压（CSPH）的患者中评估口服BI685509一种剂量（上调至固定剂量方案）治疗门静脉高压8周后临床疗效的随机、双盲、安慰剂对照、平行组试验。
NCT06193811
Relative Bioavailability of Two Different Tablet Formulations of BI 685509 and Investigation of the Effects of Food and Esomeprazole on the Pharmacokinetics of BI 685509 Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Four-way Crossover Trial)
100 项与 Avenciguat 相关的临床结果
登录后查看更多信息
100 项与 Avenciguat 相关的转化医学
登录后查看更多信息
100 项与 Avenciguat 相关的专利（医药）
登录后查看更多信息
10
项与 Avenciguat 相关的文献（医药）2024-10-01LIVER TRANSPLANTATION
Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test
Article
作者: McRae, Michael P. ; Gashaw, Isabella ; Schoelch, Corinna ; Everson, Gregory T. ; Ertle, Judith ; Lawitz, Eric J. ; Helmke, Steve M.
New methods for measuring hepatic improvement in clinical trials and the clinic are needed. One new method, HepQuant SHUNT, detected dose-dependent improvements in hepatic function and portal physiology in the phase 1b study (NCT03842761) of avenciguat, an activator of soluble guanylyl cyclase that is being developed for the treatment of portal hypertension. Herein, we examined whether HepQuant Duo, an easy-to-administer test version, could similarly detect the effects of avenciguat. Twenty-three patients with Child-Pugh A cirrhosis and liver stiffness >15 kPa received either a placebo (n = 5) or a maximum twice-daily avenciguat dose of 1, 2, or 3 mg (n = 6 per group) for 28 days. The DuO test was performed at baseline and on days 11 and 27 in each subject. The test involved administering 40 mg of d4-cholate orally, measuring d4-cholate concentrations in serum at 20 and 60 minutes, and calculating portal hepatic filtration rate, disease severity index, portal-systemic shunting (SHUNT%), and hepatic reserve (HR%). Avenciguat demonstrated dose-dependent improvement in all test parameters. Changes from baseline in SHUNT% after 27 days’ treatment were 0.1 ± 9.0% for placebo, 1.7 ± 5.5% for 1 mg twice-daily, −3.2 ± 2.7% for 2 mg twice-daily, and −6.1 ± 5.0% for 3 mg twice-daily (paired t test for change from baseline p = 0.98, 0.48, 0.04, and 0.03, respectively). The changes detected by HepQuant DuO were similar to those previously observed and reported for HepQuant SHUNT. The results support further study of avenciguat in treating portal hypertension and spotlight the utility of HepQuant DuO in the development of drug therapy for liver disease. HepQuant DuO facilitates the use of function testing to measure hepatic improvement in clinical trials and the clinic.
2024-10-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials
Article
作者: Seitz, Friedeborg ; Bauer, Verena ; Schulze, Friedrich ; Wong, Diane ; Giessmann, Thomas
Abstract:
This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 after oral single rising doses (SRDs) or multiple rising doses (MRDs) in healthy volunteers. In the SRD trial (NCT02694354; February 29, 2016), within each of the three dose groups (DGs), six subjects received BI 685509 (1.0, 2.5, or 5.0 mg) and two received placebo (N = 24). In the MRD trial (NCT03116906; April 17, 2017), within each of the five DGs, nine subjects received BI 685509 (uptitrated to 1 mg once daily [qd; DG1], 2.5 mg twice daily [DG2], 5.0 mg qd [DG3]; 3.0 mg three times daily [tid; DG4] or 4.0 mg tid [DG5]) and three received placebo, for 14–17 days (N = 60). In the SRD trial, 7/24 subjects (29.2%) had ≥ 1 adverse event (AE), most frequently orthostatic dysregulation (n = 4). In the MRD trial, 26/45 subjects (57.8%) receiving BI 685509 had ≥ 1 AE, most frequently orthostatic dysregulation and fatigue (each n = 12). Tolerance development led to a marked decrease in orthostatic dysregulation events (DG3). BI 685509 was rapidly absorbed after oral administration, and exposure increased in a dose-proportional manner after single doses. Multiple dosing resulted in near–dose-proportional increase in exposure and limited accumulation. BI 685509 pharmacokinetics appeared linear with time; steady state occurred 3–5 days after each multiple-dosing period. Increased plasma cyclic guanosine monophosphate and decreased blood pressure followed by a compensatory increase in heart rate indicated target engagement. BI 685509 was generally well tolerated; orthostatic dysregulation may be appropriately countered by careful uptitration.
2024-09-01JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Effect of Avenciguat on Albuminuria in Patients with CKD
Article
作者: Górriz, Jose Luis ; Tang, Sydney C W ; Desch, Marc ; Gafor, Abdul Halim Abdul ; Heerspink, Hiddo J L ; Iliev, Hristo ; Sun, Zhichao ; Steubl, Dominik ; Pergola, Pablo E ; Nangaku, Masaomi ; Cherney, David
Key Points:
Despite new treatments for CKD, kidney failure risk remains high, particularly where albuminuria remains.We report a prespecified pooled analysis of two randomized controlled trials assessing a soluble guanylate cyclase activator for CKD.Avenciguat led to improvements in albuminuria in patients with CKD with/without type 2 diabetes mellitus, with acceptable safety.
Background:
Avenciguat is a novel, potent soluble guanylate cyclase activator in development for CKD. Two trials investigated avenciguat in diabetic (NCT04750577) and non-diabetic (NCT04736628) CKD.
Methods:
A prespecified pooled analysis of two randomized, double-blind, placebo-controlled trials of identical design. Adults with CKD (eGFR ≥20 and <90 ml/min per 1.73 m2, urine albumin–creatinine ratio [UACR] ≥200 and <3500 mg/g) were randomized to 20 weeks of placebo or avenciguat 1, 2, or 3 mg three times daily (TID), adjunctive to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary end point was change from baseline in UACR in 10-hour urine at week 20, analyzed per protocol. The secondary end point was UACR change from baseline in first morning void urine at week 20. Safety was monitored throughout.
Results:
Overall, 500 patients (mean age 62 years [SD 13]; mean eGFR 44 ml/min per 1.73 m2 [SD 18] and median 10-hour UACR 719 [interquartile range, 379–1285] mg/g) received placebo (n=122) or avenciguat 1 mg (n=125), 2 mg (n=126), or 3 mg (n=127) TID. All 243 patients in study one and 27 of 261 patients in study two had diabetes mellitus. Avenciguat 1, 2, and 3 mg TID reduced UACR in 10-hour and first morning void urine versus placebo throughout the treatment period. At week 20, placebo-corrected geometric mean changes (95% confidence interval) from baseline in UACR in 10-hour urine with avenciguat 1, 2, and 3 mg TID were −15.5% (−26.4 to −3.0), −13.2% (−24.6 to −0.1), and −21.5% (−31.7 to −9.8), respectively, analyzed per protocol. Corresponding changes in first morning void urine were −19.4% (−30.0 to −7.3), −15.5% (−26.9 to −2.5), and −23.4% (−33.5 to −11.8), respectively. Avenciguat was well tolerated; the overall frequency of adverse events was low and similar to placebo. The number of patients who discontinued the study drug because of adverse events with avenciguat 1, 2, and 3 mg TID were five (4%), 11 (9%), and 11 (9%), respectively, compared with four (3%) in the placebo group.
Conclusions:
Avenciguat lowered albuminuria and was well tolerated in patients with CKD.
Clinical Trial registry name and registration number::
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease, NCT04750577, and A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease, NCT04736628.
Podcast:
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_06_27_ASN0000000000000418.mp3
100 项与 Avenciguat 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝硬化 | 临床2期 | 澳大利亚 | 2024-02-27 | |
| 肝硬化 | 临床2期 | 澳大利亚 | 2024-02-27 | |
| 系统性硬皮病 | 临床2期 | 美国 | 2022-12-14 | |
| 系统性硬皮病 | 临床2期 | 美国 | 2022-12-14 | |
| 系统性硬皮病 | 临床2期 | 日本 | 2022-12-14 | |
| 系统性硬皮病 | 临床2期 | 日本 | 2022-12-14 | |
| 系统性硬皮病 | 临床2期 | 阿根廷 | 2022-12-14 | |
| 系统性硬皮病 | 临床2期 | 阿根廷 | 2022-12-14 | |
| 系统性硬皮病 | 临床2期 | 澳大利亚 | 2022-12-14 | |
| 系统性硬皮病 | 临床2期 | 澳大利亚 | 2022-12-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 261 | (Avenciguat 1 mg TID) | 築鹽繭積鹹鏇壓憲艱積(簾衊觸憲鹹醖選襯顧鹹) = 遞鏇壓網鹽憲構膚糧淵 衊襯簾鹽遞鏇襯餘糧顧 (廠繭鏇鹹醖鹹獵壓壓簾, 築壓艱壓鹽鏇鹽鹹齋淵 ~ 餘顧鬱衊繭範窪鹹鹽積) 更多 | - | 2024-09-04 | ||
(Avenciguat 2 mg TID) | 築鹽繭積鹹鏇壓憲艱積(簾衊觸憲鹹醖選襯顧鹹) = 醖壓顧積蓋鬱顧鏇遞鑰 衊襯簾鹽遞鏇襯餘糧顧 (廠繭鏇鹹醖鹹獵壓壓簾, 範餘構製齋鹹齋繭構蓋 ~ 糧繭繭淵範獵獵醖鹽遞) 更多 | ||||||
临床2期 | 243 | (BI 685509 1 mg TID) | 範鑰鹽餘網衊鹽廠繭蓋(鏇顧鏇築遞鏇遞範窪獵) = 網壓鏇網顧積廠鹽範範 遞顧鑰糧衊積鬱築糧餘 (鏇築鏇鏇蓋廠簾築艱鏇, 鏇糧獵壓憲襯築鏇窪範 ~ 鏇糧糧壓夢憲衊積鹽繭) 更多 | - | 2024-07-23 | ||
(BI 685509 3 mg TID) | 範鑰鹽餘網衊鹽廠繭蓋(鏇顧鏇築遞鏇遞範窪獵) = 網廠憲製築選網醖壓繭 遞顧鑰糧衊積鬱築糧餘 (鏇築鏇鏇蓋廠簾築艱鏇, 繭鹽製淵簾顧蓋範鬱鏇 ~ 鹽選鑰鬱築蓋夢襯鑰簾) 更多 | ||||||
临床2期 | 500 | Avenciguat 1 mg TID | 選築鏇廠觸壓獵艱蓋鏇(範獵憲繭網築獵艱糧淵) = 壓廠遞淵範齋鬱鹽願鹹 糧構蓋鏇鹹壓鏇製窪構 (艱鏇築選鏇鹹糧蓋製淵, -26.4 ~ -3.0) 更多 | 积极 | 2024-05-25 | ||
Avenciguat 2 mg TID | 選築鏇廠觸壓獵艱蓋鏇(範獵憲繭網築獵艱糧淵) = 鑰鬱願鹽鑰衊醖艱壓膚 糧構蓋鏇鹹壓鏇製窪構 (艱鏇築選鏇鹹糧蓋製淵, -24.6 ~ -0.1) 更多 | ||||||
临床2期 | 50 | BI-685509 30 mpk/day | 齋齋遞蓋顧鹽糧淵醖夢(憲簾觸築鏇糧簾構簾鹹) = 選襯鏇醖壓膚廠鹹製憲 鹹網衊築網蓋積醖獵醖 (鹹積糧顧壓觸鬱醖顧艱 ) 更多 | 积极 | 2022-11-05 | ||
BI-685509 100 mpk/day | 齋齋遞蓋顧鹽糧淵醖夢(憲簾觸築鏇糧簾構簾鹹) = 衊繭餘願築鏇繭選齋鹹 鹹網衊築網蓋積醖獵醖 (鹹積糧顧壓觸鬱醖顧艱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用